中国药物经济学2024，Vol.19Issue(2)：5-7,16,4.DOI:10.12010/j.issn.1673-5846.2024.02.001
基于Markov模型的利培酮与阿立哌唑治疗精神分裂症的药物经济学评价
Pharmacoeconomic Evaluation of Risperidone and Aripiprazole for Schizophrenia based on Markov Model
摘要
Abstract
Objective To evaluate the long-term economic benefits of risperidone and aripiprazole in the treatment of schizophrenia using markov model.Methods Based on the published data of clinical randomized controlled trials on risperidone and aripiprazole in the treatment of schizophrenia,a Markov model of the treatment of schizophrenia with two drugs was constructed and the parameters of the model were set.The health outcomes and resource consumption of the two drugs for schizophrenia were compared,and cost-effectiveness and sensitivity analyses were performed.Results Markov simulated risperidone and aripiprazole to treat schizophrenia for 3 years,with an average cost of $14396 and $16147,respectively,and gained 14.03 and 13.77 quality-adjusted life years(QALYs),respectively.The risperidone treatment regimen cost $1751 less for each additional QALY received.When the drug price drops by 10%or 20%,there is no effect on the result,and risperidone is still the preferred solution.Conclusion Compared with aripiprazole,the risperidone treatment regimen offers greater cost savings and is a superior regimen for the clinical treatment of schizophrenia.关键词
Markov模型/利培酮/阿立哌唑/药物经济学/精神分裂症Key words
Markov model/Risperidone/Aripiprazole/Pharmacoeconomics/Schizophrenia分类
医药卫生引用本文复制引用
洪怀章,朱惠娟,林娟,严静雯,田映青..基于Markov模型的利培酮与阿立哌唑治疗精神分裂症的药物经济学评价[J].中国药物经济学,2024,19(2):5-7,16,4.基金项目
惠州市科技计划项目(2021WC0106250) （2021WC0106250）
